Abstract
Therapy with angiogenesis inhibitors carries the risk for health and life-threatening cardio-vascular complications. The most common include the development of arterial hypertension, thromboembolic events (venous and arterial) and bleeding. This study provides a detailed analysis of their incidence, pathomechanisms as well as methods of prophylaxis and treatment among ovarian cancer patients receiving bevacizumab.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
